

BIBLIOGRAFÍA USADA EN EL PROCESO INFARTO AGUDO DE MIOCARDIO CON ELEVACIÓN DEL ST (IAMST) (además de la referida en el Proceso de Dolor Torácico no filiado)

1. Armstrong PW, Steerng W. A comparison of pharmacologic therapy with/without timely coronary intervention v. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (wich early ST-elevation myocardial infarction therapy) study. *Eur Heart J* 2006;27:1530-1538.
2. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med* 2003;349:733–742.
3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). *J Am Coll Cardiol.* 2004 Aug 4;44(3):E1-E211.
4. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE–Thrombolysis in Myocardial Infarction (TIMI) 23 trial. *Circulation* 2002;105:1642–1649.
5. Antman EM, Morrow DA, McCabe CH, et al. for the ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. *N Engl J Med* 2006;354:1477-1488.
6. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. *Lancet* 2006;367:569 –578.
7. Boersma E The Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. PACT Investigators. *Eur Heart J* 2006;27(7):779-88.
8. Bonnefoy E, Lapostolle F, Leizorovicz A, et al, on behalf of the CAPTIM Study Group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. *Lancet* 2002;360:825–829.
9. Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. *N Engl J Med* 2006;355:2308-2220.

10. Brodie BR, Hansen Ch, Stuckey Th D et al. Door-to-Balloon Time With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Impacts Late Cardiac Mortality in High-Risk Patients and Patients Presenting Early After the Onset of Symptoms *J Am Coll Cardiol* 2006;47:289–95.
11. Cannon C, Braunwald E, McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes *N Engl J Med* 2004;350:1495-504.
12. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. *JAMA* 2000;283:2941–2947.
13. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet* 2005;366:1607-1621.
14. Dalby M, Bouzamondo A, Lechat P, et al. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a metaanalysis. *Circulation* 2003; 108:1809-1814.
15. Danchin N, Blanchard D, Steg Ph G, et al for the USIC 2000 Investigators Impact of Prehospital Thrombolysis for Acute Myocardial Infarction on 1-Year Outcome Results From the French Nationwide USIC 2000 Registry. *Circulation* 2004;110:1909-1915.
16. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001;357:1385–1390.
17. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. *Circulation* 2004;109:1223–1225.
18. De Luca G, Suryapranata H, Stone GW, et al Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction. A Meta-analysis of Randomized Trials. *JAMA*. 2005;293:1759-1765.
19. DeLuca G, Suryapranata H, Zijlstra F, et al. Symptom-onset-to balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. *J Am Coll Cardiol* 2003;42:991–997.
20. Dzavik V, Buller Ch E, Lamas GA, et al for the TOSCA-2 Investigators. Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function. The Total Occlusion Study of Canada (TOSCA)–2 Trial. *Circulation* 2006;114:2449-2457.
21. Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. A Meta-Analysis of the Randomized Trials. *Circulation* 2005;112:3855-3867.

22. Fernández-Avilés F, Alonso JJ, Peña G, et al, for the GRACIA-2 (Grupo de Análisis de la Cardiopatía Isquémica Aguda) Investigators. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. *Eur Heart J* 2007;28: 949-960.
23. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 h of thrombolysis versus ischaemia—Guided Conservative Approach for Acute Myocardial Infarction With ST-Segment Elevation (GRACIA-1): a randomized controlled trial. *Lancet* 2004;364:1045–1053.
24. Gershlick A, Stephens-Lloyd A, Hughes S, et al, for the REACT Trial Investigators. Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction. *N Engl J Med* 2005;353:2758-2768.
25. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. *Circulation* 2006;113: 2906-2913.
26. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST elevation myocardial infarction in patients with contraindications to thrombolytic therapy. *JAMA* 2003;290:1891-1898.
27. Halkin A, Grines CL, Cox DA, et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *J Am Coll Cardiol* 2004;43:1780-1787.
28. Hochman JS, Lamas GA, Buller CE, et al. The Occluded Artery Trial Investigators (OAT). Coronary Intervention for Persistent Occlusion after Myocardial Infarction. *N Engl J Med* 2006; 355:2395-2407.
29. Hochman JS, Sleeper LA, Webb JG, et al for the SHOCK investigators. Early revascularization and long term survival oin cardiogenic shock complicating acute myocardial infarction. *JAMA* 2006;295:2511-2515.
30. Jacobs AJ, Antman EM, Ellrod G, et al. Recommendation to Develop Strategies to Increase the Number of ST-Segment–Elevation Myocardial Infarction Patients With Timely Access to Primary Percutaneous Coronary Intervention. The American Heart Association’s Acute Myocardial Infarction (AMI) Advisory Working Group. *Circulation* 2006;113:2152-2163.
31. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. *Lancet* 2006; 367:579-588.
32. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. *Lancet* 2006;367:579 –58.
33. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet* 2003; 361:13-20.

34. Keeley EC, Grines CL. Should patients with acute myocardial infarction be transferred to a tertiary center for primary angioplasty or receive it at qualified hospitals in the community? The case for emergency transfer for primary percutaneous coronary intervention. *Circulation* 2005; 112:3520-3532.
35. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? *J Am Coll Cardiol* 2004;43:1773-1779.
36. Kostis WJ, Demissie K, Marcella SW, et al., for the Myocardial Infarction Data Acquisition System (MIDAS 10) Study Group. Weekend versus Weekday Admission and Mortality from Myocardial Infarction. *N Engl J Med* 2007;356:1099-109.
37. Laarman GJ, Suttrop MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. *N Engl J Med* 2006;355:1105-1113.
38. Le May M, Wells GA, Labinaz M, et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study). *J Am Coll Cardiol* 2005;46:417-424.
39. McMurray J, Pfeffer MA, Swedberg K, et al. Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction? *Circulation* 2004;110:3281-3288.
40. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;346:877-883.
41. Nallamothu BK, Wang Y, Magid DJ, et al. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST segment elevation myocardial infarction: National Registry of Myocardial Infarction- 4 analysis. *Circulation* 2006;113:222-229.
42. Pedersen TR, Faergeman O, Kastelein JJP, et al for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction .The IDEAL Study: A Randomized Controlled Trial. *JAMA* 2005;294:2437-2445.
43. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;349:1893-906.
44. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction Implications When Selecting a Reperfusion Strategy. *Circulation* 2006;114:2019-2025.
45. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003;348:1309 -1321.

46. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med* 1999;341:709–717.
47. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med* 2005;352:1179-1189.
48. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pre-treatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. *JAMA* 2005;294:1224-1232.
49. Scheller B, Hennen B, Hammer B, et al for the SIAM III Study Group. Beneficial Effects of Immediate Stenting After Thrombolysis in Acute Myocardial Infarction. *J Am Coll Cardiol* 2003;42:634–641.
50. Schömig A, Mehilli J, Antoniucci D, al. for the Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators. Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset A Randomized Controlled Trial. *JAMA*. 2005;293:2865-2872.
51. Silber S et al. Guías de práctica clínica sobre intervencionismo coronario percutáneo. Grupo de trabajo de la Sociedad Europea de Cardiología sobre intervención coronaria percutánea. *Rev Esp Cardiol* 2005;58:679-728.
52. Simoons M, Krzeminska-Pakula M, Alonso A, et al, for the AMI-SK Investigators. Improved reperfusion and clinical outcome with enoxaparin as an adjuvant to streptokinase thrombolysis in acute myocardial infarction: The AMI-SK study. *Eur Heart J* 2002;23:1282–1290.
53. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). *Circulation* 2006;113(7):e166-286.
54. Smith SC, Allen J, Blair SN et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update *J Am Coll Cardiol*. 2006;47;2130-2139.
55. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. *N Engl J Med* 2006;355:1093-1104.
56. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. *Circulation* 2006;113:2803-2809.
57. Steg PG, Bonnefoy E, Chabaud S, et al. Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation* 2003;108:2851-2856.
58. Stenestrand U, Lindback J, Wallentin L; RIKS-HIA Registry Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction. *JAMA* 2006;296:1749-1756.

59. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. *N Engl J Med* 2002;346: 957-966.
60. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. *Lancet* 2001;358:605– 613.
61. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. *JAMA* 2005;293:2109-2117.
62. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 2003; 24, 28–66.
63. Wallentin L, Bergstrand L, Dellborg M, et al for the ASSENT PLUS Investigators. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction: the ASSENT Plus study. *Eur Heart J* 2003;24:897–908.
64. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. *Circulation* 2003;108:135–142.
65. White HD, Braunwald E, Murphy SA, et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. *Eur Heart J* 2007;28:1066-1071.
66. Widimsky P, Bilkova D, Penicka M, et al. Of the PRAGUE Study Group Investigators. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 trial. *Eur Heart J* 2007 28: 679-684.
67. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. *Eur Heart J* 2003;24:94 –104.
68. Wijeyesundera HC, Vijayaraghavan R, Nallamotheu BK, et al. Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis of Randomized Trials .*J Am Coll Cardiol* 2007 49: 422-430.
69. Zeymer U, Uebis R, Vogt A, et al, for the ALKK-Study Group. Randomized Comparison of Percutaneous Transluminal Coronary Angioplasty and Medical Therapy in Stable Survivors of Acute Myocardial Infarction With Single Vessel Disease. *Circulation* 2003;108:1324-1328.

BIBLIOGRAFÍA CONSULTADA EN EL SUBPROCESO: CUIDADOS DE ENFERMERÍA EN PACIENTES CON DOLOR TORÁCICO POTENCIALMENTE GRAVE (además de la referida en el Proceso de Dolor Torácico no filiado)

1. Aldasoro, Elena; Calvo, Montse; Esnaola, Santiago; Hurtado de Saracho, Iraida; Alonso, Eva; Audicana, Covadonga; Arós, Fernando; Lekuona, Iñaki; Arteagoitia, José M; Basterretxea, Mikel; Marrugat, Jaime. Diferencias de género en el tratamiento de revascularización precoz del infarto agudo de miocardio. *Med Clínica* 2007;128:81-85.
2. Ariza Olarte, Claudia. Atención de enfermería al paciente con infarto agudo de miocardio en la fase aguda. *Rev Enferm Cardiol* 2001;8:33-40.
3. Azaldegui Berroeta, F. Manejo extrahospitalario del dolor torácico no traumático. *Sal Rural* 2004;21:17-38.
4. García Mora, Sandra Isabel. Enfermería ante el dolor torácico de origen cardiológico en una unidad de hospitalización. *Rev Enferm Cardiol* 2005;12:45-49.
5. Goldich, Guy. Infarto de miocardio: los nuevos protocolos *Nursing* 2006;9:30-33.
6. Gregoire J. Evaluating thoracic pain in triage. *Perspect Infirm.* 2006; 3:33-6.
7. Jenifer M; Miracle V. Utilización del ECG para detectar el infarto de miocardio. *Nursing* 2000;18(1):17-22.
8. López de la Iglesia, J; Martínez Ramos, E; Pardo Franco, L; Escudero Álvarez, S; Cañón de la Parra, Rl; Costas Mira, MT. Encuesta a los pacientes con cardiopatía isquémica sobre el modo de actuación ante los distintos síntomas de alarma. *Aten Primaria* 2003; 31:239-247.
9. Martín-Rabadán, M. No informamos a los pacientes con cardiopatía isquémica sobre 'cómo actuar' al reaparecer el dolor torácico. *GCS* 2003; 5(4):143.
10. McCloskey, DJ; Bulechek, TG; editoras. Clasificación de intervenciones en enfermería (NIC). 4ª ed. Madrid: Mosby; 2005.
11. Moorhead, S; Jhonson, M; Maas, M; editoras. Clasificación de resultados de enfermería (NOC). 3ª ed. Madrid: Mosby; 2005.
12. NANDA. Nanda Diagnósticos enfermeros: definiciones y clasificación 2005-2006. Madrid: Elsevier; 2007.
13. Nolan, J; Greenwood, J; Mackintosh, A. Atención Urgente y primeros cuidados al paciente con infarto agudo de miocardio. *Salud Rural*,1999; 16:69-72.
14. Portuondo Maseda, MT; Marugán Torres, P; Cabrero Fernández, F; Morales Durán, M; Maroto Montero, JM; Muriel, A. Sobrepeso y deshabitación tabáquica. *Rev Enferm Cardiol* 2006; 13:41-43.
15. Silva Paiva , G da; Oliveira Lopes, MV. Respuestas humanas identificadas en pacientes con infarto agudo del miocardio ingresados en una unidad de terapia intensiva. *Rev Enferm Cardiol* 2005; 12:22-27.

BIBLIOGRAFÍA CONSULTADA EN EL SUBPROCESO DE PREVENCIÓN SECUNDARIA Y REHABILITACIÓN CARDÍACA (además de la referida en el Proceso de Dolor Torácico no afiliado)

1. Balady GF, et al. Cardiac Rehabilitation programs : a statement for healthcare professionals from the American Heart Association. *Circulation* 1994;90:1602-1610.
2. Best Practice Evidence-based Guideline CARDIAC REHABILITATION AUGUST 2002 © 2002 New Zealand Guidelines Group (NZGG) PO Box 10 665, The Terrace, Wellington, New Zealand Published: August 2002 Review Date: 2005 ISBN: 0-473-08825-8.
3. Best Practice Guidelines for Cardiac Rehabilitation and Secondary Prevention. Goble AJ & Worcester MUC Heart Research Centre Published by Department of Human Services Victoria Australia April 1999 ISBN: 0 7311 5258 1.
4. Boraita A. et al. Guía de Práctica Clínica de la Sociedad Española de Cardiología sobre la actividad física en el cardiópata, *Rev. Esp. Cardiol*, 2000; 53: 684-726.
5. Del Rio A, De Pablo C. Manual de Cardiología Preventiva. Sociedad Española de Cardiología 2005. ISBN: 84-7592-767-X.
6. Entrala A. Medidas generales en prevención primaria y secundaria de episodios cardiovasculares. Importancia del ejercicio físico y de la dieta. *Clínica e investigación en Arterioesclerosis*. Vol 13, Supl 1, 2001. Pag. 53-56.
7. Espinosa J.S., Bravo Navas J.C; Rehabilitación Cardíaca y Atención Primaria. Grupo de Trabajo de Rehabilitación Cardíaca y Prevención Secundaria de la SEC. Editorial Panamericana 2000.
8. Evidence-Based Cardiac Practice Guidelines Cardiac Rehabilitation. Scottish Intercollegiate Guidelines Network. 2002 ISBN: 189989392X. First published 2002.
9. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. A American Heart Association Scientific Statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), *Circulation* 2003;107:3109-3116.
10. Leon AS, et al. Cardiac Rehabilitation and Secondary Prevention of Coronary Heart Disease. An American Heart Association Scientific Statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in Collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation. *Circulation* 2005;111:369-376.
11. Lori Mosca, MD et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update, *Circulation*. March 20, 2007;115:0000-0000.
12. Maroto J.M et al. Rehabilitación Cardíaca. Editorial Olalla Cardiología. 1ªEdición 1999.
13. Márquez-Calderón S. et al Implantación y características de los programas de rehabilitación cardiaca en el Sistema Nacional de Salud español. *Rev sp. Cardiol* 2003; 56 (8): 775-82.

14. Piña et al. Exercise and Heart Failure. A Statement from the American Heart Association Committee on Exercise, Rehabilitation and Prevention. *Circulation* 2003;107:1210-1225.
15. Taylor RS. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized trials. *Am J Med.* 2004; 116:682-697.
16. Velasco JA, et al. Guía de Práctica Clínica en Prevención Cardiovascular y Rehabilitación Cardíaca de la Sociedad Española de Cardiología. *Rev. Esp. Cardiol.* 2000; 53: 1095-1020.